UK-VNCCLL-230003. Date of Preparation: March 2023.
VENCLYXTO (venetoclax) has three licenced indications1
VENCLYXTO in combination with obinutuzumab (Ven+O) is indicated for the treatment of adult patients with previously untreated CLL
VENCLYXTO in combination with rituximab (Ven+R) is indicated for the treatment of adult patients with CLL who have received at least one prior therapy
VENCLYXTO is licensed as monotherapy (Ven mono), for the treatment of adult patients with CLL:
- in the absence of del(17p) or TP53 mutations and who have failed both chemoimmunotherapy and a BCRI
- in the presence of del(17p) or TP53 mutations and who are either unsuitable for, or have failed a BCRI
BRCI=B-cell receptor pathway inhibitor; CLL=Chronic lymphocytic leukaemia; CR=Complete remission; ORR=Overall response rate; PR=Partial response; SmPC=Summary of product characteristics.
- VENCLYXTO Summary of Product Characteristics.
- Seymour JF et al. N Engl J Med. 2018; 378(12): 1107–20.
- Fischer K et al. N Engl J Med. 2019; 380: 2225–36.
- Al-Sawaf O et al. EHA2021 Abstract S146. https://library.ehaweb.org/eha/2021 (accessed April 2023).
- Kater AP et al. ASH 2020. Oral Abstract 125. Available from: https://ash.confex.com/ash/2020 (accessed April 2023).
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on [email protected]
UK-VNCCLL-230163. Date of preparation: April 2023.